Dr. Chao Dong 董朝
Chief Physician, Associate Professor
Head and Neck Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of breast, thyroid, and head and neck tumors. Focuses on early diagnosis and complex procedures, including endoscopic thyroidectomy, breast reconstruction, sentinel lymph node biopsy, and reconstructive surgery for head and neck defects.
Dr. Dong holds a master’s degree and graduated from the Affiliated Cancer Hospital of Xinjiang Medical University in 2001. The doctor conducts research on breast, thyroid, and head and neck tumor surgery. Dr. Dong has published over 20 papers and participated in multiple National and Autonomous Region Natural Science Foundation projects.
Professional roles
- Youth Committee Member, Thyroid Cancer Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Head and Neck Tumor Professional Committee, China Medical Education Association
- Member, Breast Professional Committee, China Healthcare Promotion Association
Name order: in Chinese the family name comes first (Dong Chao). Papers usually list the name as Chao Dong or Dong C.
Selected publications
37 papers on PubMed matched by name and affiliation; 8 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): The prognostic value of the pan-immune-inflammation value in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. PubMed 42666221
- Front Oncol, 2026 (senior author): Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. PubMed 42294282
- Front Oncol, 2026 (senior author): Prognostic value of prognostic nutritional index in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. PubMed 42125682
- Mutat Res, 2026 (senior author): Role of c-Myc-regulated miR-196a-5p in the progression of triple-negative breast cancer: Potential involvement of HOXA7 and HOXB7. PubMed 41385964
- Front Immunol, 2025 (senior author): Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. PubMed 40909265
- Breast Cancer, 2025 (first author): c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a. PubMed 40029493
- Clin Cosmet Investig Dermatol, 2022 (senior author): Thyroidectomy Using the Lateral Cervical Small Incision Approach for Early Thyroid Cancer. PubMed 35478775
- Bioengineered, 2022 (senior author): The role of microRNA-4723-5p regulated by c-myc in triple-negative breast cancer. PubMed 35382692
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion